July 14 (Reuters) - Biotech company Roivant Sciences (ROIV.O) is in talks to sell an experimental drug to treat inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, to Roche (ROG.S) in a deal that could be valued at more than $7 billion, the Wall Street Journal reported on Thursday. The sale of the drug could be announced in the coming days, the report said citing people familiar with the matter. RVT-3101 showed improvement in inflammation and ulcers in the colon when compared to a placebo in a mid-stage study in June. Roivant and Roche declined to comment on the matter. Reporting by Shivani Tanna and Sriparna Roy in Bengaluru; Editing by Shailesh Kuber and Krishna Chandra EluriOur Standards: The Thomson Reuters Trust Principles.

Source: Wall Street Journal July 14, 2023 13:36 UTC